Dr Reddy's Labs

North America weakness, lower margins, uncertainty over key launches weigh on earnings outlook

The expanding domestic market for semaglutide-based weight-loss drugs is expected to help cushion weaker US sales for Cipla and Dr Reddy's after the loss of Revlimid exclusivity

Dr Reddy's Foundation -- a family-owned trust and one of the key beneficiaries of the CSR funds of pharma major Dr Reddy's Laboratories -- is scaling up operations at its Hyderabad soil testing facility with the lab targeting between 75,000 and 1,00,000 samples ahead of the next Rabi season -- more than double what it processed in its first full year of operations. The move comes amid growing concern over depleting soil health and implementation gaps in the Centre's Soil Health Card scheme rolled out nationally in 2015. "Though the government's soil testing ecosystem exists, the scale of the problem is huge. So we decided to address this issue in our own way," said Suman Saraswathibatla, Director (Rural Livelihoods and Climate Action) at the foundation. This soil testing facility is central to the Foundation's broader soil health and regenerative agriculture programme, under which assessing soil condition is treated as the starting point for any intervention. The push for an in-hou

Drugmaker said certain batches of semaglutide failed to meet quality specifications, prompting a delay in commercial supplies, while maintaining there is no impact on patient safety

Dr Reddy's Laboratories on Saturday said it has launched its generic version of Semaglutide injection used in treatment of type 2 diabetes in Canada. The company is among the first firms to introduce a generic Semaglutide injection in the Canadian market, following the Notice of Compliance (NOC) received from Health Canada on April 28, 2026, Dr Reddy's said in a statement. Canada is the first G7 country to grant market authorisation for Semaglutide injection, it added. "The milestone highlights our readiness to serve the Canadian patients, supported by our deep expertise in complex drug and peptide development," Dr Reddy's CEO Erez Israeli said. He further said:"With a well-established presence and strong market access capabilities in Canada, we remain committed to bringing advanced, high-quality, and affordable GLP-1 therapies closer to patients." The Canada launch builds on the momentum of the company's recent launch in India under the brand name Obeda, Israeli said. "As GLP-1

Dr Reddy's net profit is expected to come at ₹1,035 crore, marking a moderate 34 per cent Y-o-Y decrease, on average, as against ₹1,587 crore in the Q4FY25

Dr Reddy's Laboratories has forayed into hormone replacement therapy segment by acquiring trademarks of specialty brands, Progynova and Cyclo-Progynova and related assets, for India from UK-headquartered Mercury Pharma Group for USD 32.15 million, according to a company statement. Progynova (estradiol valerate) is an oral hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms and for the prevention of postmenopausal osteoporosis. Cyclo-Progynova (estradiol valerate and norgestrel) is a combined hormone replacement therapy indicated for the treatment of estrogen deficiency symptoms, providing both estrogen and progestogen components. As per IQVIA MAT December 2025, the brand recorded sales of Rs 100 crore. The acquisition strengthens Dr Reddy's gynaecology portfolio and marks a strategic entry into the hormone replacement therapy segment, the drug firm stated. "The acquisition will serve as the spearhead of our expansion into the HRT segment, ...

Wegovy's monthly price in India ranges from ₹10,850 ($119.65) for the lowest 0.25 mg dose to ₹16,400 for the highest 2.4 mg dose

At 12:30 PM, Dr. Reddy's shares were trading 2.03 per cent higher at ₹1,249.65 per share. In comparison, BSE Sensex was trading flat with a positive bias at 84,943.47 levels.

Indian cos like Biocon, DRL, Intas, Lupin stand to benefit from the proposed move

Dr Reddy's net profit is expected to come at ₹1,479 crore, marking a moderate 5.5 per cent Y-o-Y increase, on average, as against ₹1,401 crore in the year-ago period

Dr Reddy's Labs Q1 preview: The company's net profit is expected to come at ₹1,460 crore, marking around 4.9 per cent Y-o-Y increase, on average, as against ₹1,392.4 crore in Q1 FY25

The fall in Dr. Reddy's share price came after the company announced that it received approximately Rs 2,395-crore show cause notice from I-T department

Dr Reddy's Laboratories Ltd on Saturday said it has received a showcause notice from the income tax authority with a proposed demand of over Rs 2,395 crore from it related to the merger of Dr Reddy's Holding Ltd (DRHL) with itself. The company has received a show cause notice on April 4, 2025, from the office of the Assistant Commissioner of Income Tax, Hyderabad, Dr Reddy's Laboratories Ltd said in a regulatory filing. It requires the company to respond as to why notice should not be issued for assessment of income alleged to be escaped from tax consequent to the merger of DRHL into Dr Reddy's Laboratories Ltd (DRL) under the scheme of amalgamation approved by the National Company Law Tribunal (NCLT), Hyderabad on April 5, 2022, the filing added. "The notice quantifies the proposed demand of Rs 23,95,81,79,470," the company said. DRL asserted that said scheme of amalgamation was carried with adherence to all the legal requirements including tax laws. "Further this was approved by

The growth was largely driven by revenue from its recently acquired nicotine replacement therapy (NRT) portfolio and performance in the European and emerging markets

Atomoxetine is used for treating attention deficit hyperactivity disorder (ADHD) in adults and children over six years.

Dr Reddy's Laboratories Ltd on Thursday said the US health regulator has issued Form 483 with two observations after inspecting its manufacturing facility located at Srikakulam in Andhra Pradesh. As per USFDA, Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that in its judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The US Food and Drug Administration (USFDA) completed a pre-approval inspection at the company's formulations manufacturing facility FTO 11 in Srikakulam, Andhra Pradesh on Thursday, Dr Reddy's said in a regulatory filing. The inspection was conducted from June 30, 2022 to July 7, 2022. "We have been issued a Form 483 with two observations, which we will address within the stipulated timeline," the company added.

Dr Reddy's Laboratories on Thursday said its subsidiary has inked a pact with US-based Olema Pharmaceuticals Inc to research, develop and commercialise novel small molecule inhibitors of a target

Sputnik Light has not yet received emergency use authorisation from the DCGI

The overall chart pattern of Asian Paints indicates that the prevailing momentum is likely to continue